Complete vs Incomplete Metastasectony for mRCC: Improved Survival, Decreased All-Cause Mortality

Complete vs Incomplete Metastasectony for mRCC: Improved Survival, Decreased All-Cause Mortality

Complete surgical metastasectomy correlated with increased survival in patients with metastatic renal cell carcinoma (mRCC) compared with incomplete surgical metastasectomy.

Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer

Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer

Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.

Use of Checkpoint Inhibitors in Urothelial Carcinoma

Use of Checkpoint Inhibitors in Urothelial Carcinoma

Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.

GUCS 2017: Early Immunotherapy Discontinuation in mRCC

GUCS 2017: Early Immunotherapy Discontinuation in mRCC

Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.

ABX May Impact Efficacy of Checkpoint Inhibitors in RCC

ABX May Impact Efficacy of Checkpoint Inhibitors in RCC

Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.

Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC

Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC

Alternating treatment with pazopanib and everolimus failed to prolong progression-free survival compared with continuous pazopanib.

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.

Smoking-related Cancer Deaths Highest in Southern United States

Smoking-related Cancer Deaths Highest in Southern United States

Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.

Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection

Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection

[OncoTargets and Therapy] This research We reviews the development of cabozantinib in advanced renal cell carcinoma and its role in the treatment landscape.

New Class of Drugs Shows Promise Against Kidney Cancer

New Class of Drugs Shows Promise Against Kidney Cancer

A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).

Double Autologous HCT Improves Outcomes in High-risk Pediatric Neuroblastoma

Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.

Surgery Improves Survival in Metastatic Kidney Cancer, But Is Little Used

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.

Drug-Resistant Cancer May Be Combatted With New Generation mTOR Inhibitors

A potential cancer therapy with a unique strategy to block the mTOR molecule has been designed. This new mTOR-inhibiting compound reduced the size of tumors resistant to earlier-generation mTOR inhibitors.

Genetic Differences Explain Survival Disparity in African Americans With Kidney Cancer

Several genetic differences uncovered in an analysis of data from The Cancer Genome Atlas (TCGA) are biologically plausible contributing factors for the worse survival of African American patients with clear cell renal carcinoma, even in the era of targeted therapy.

New Therapy Holds Potential for Neuroblastoma Treatment

New Therapy Holds Potential for Neuroblastoma Treatment

A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.

Adjuvant Sorafenib or Sunitinib Not Effective for Local Kidney Cancer

Adjuvant Sorafenib or Sunitinib Not Effective for Local Kidney Cancer

Adjuvant treatment with sorafenib or sunitinib demonstrated no survival benefit in patients with resected local renal cell carcinoma at high risk for disease recurrence.

Tumor Heterogeneity as a Rationale for a Multi-epitope Approach in an Autologous Renal Cell Cancer Tumor Vaccine

Tumor Heterogeneity as a Rationale for a Multi-epitope Approach in an Autologous Renal Cell Cancer Tumor Vaccine

In this study, researchers sought to characterize a panel of 36 tumor-associated antigens and cellular marker proteins from tumor material of 133 patients with renal cell carcinoma who underwent radical neprhectomy.

Renal Mass Biopsy Proves Accurate for Small Renal Masses

Renal Mass Biopsy Proves Accurate for Small Renal Masses

For smaller renal masses sized at 4 cm or less, mass biopsy is accurate.

Progression-free Survival in Advanced Renal Cell Carcinoma Is Improved With Cabozantinib

Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.

Study Evaluates Effect of Everolimus-induced Stomatitis

Study Evaluates Effect of Everolimus-induced Stomatitis

Everolimus-induced stomatitis did not negatively affect progression-free survival in patients with various types of cancer, such as breast cancer and renal cell carcinoma.

ASCO: Cabozantinib Increases Progression-Free Survival in RCC

ASCO: Cabozantinib Increases Progression-Free Survival in RCC

Improvements to progression-free survival (PFS) seen across patient subgroups treated with cabozantinib.

Nivolumab Now FDA Approved for Advanced RCC

Nivolumab Now FDA Approved for Advanced RCC

This newly approved drug operates by targeting the PD-1/PD-L1 cellular pathway.

Diabetes Linked to Worse Survival in Renal Cell Carcinoma

Diabetes Linked to Worse Survival in Renal Cell Carcinoma

For patients with diabetes, poor glycemic control is linked to higher risk of postoperative progression.

Nivolumab Indications Extended to Include Advanced Renal Cell Carcinoma

Nivolumab Indications Extended to Include Advanced Renal Cell Carcinoma

The FDA extended indications for nivolumab (Opdivo) to include treatment of advanced (metastatic) renal cell carcinoma (RCC).

Cause of a Childhood Kidney Cancer Is a Previously Unrecognized Role of a Known Gene

Cause of a Childhood Kidney Cancer Is a Previously Unrecognized Role of a Known Gene

Genetic mutations in the REST gene have been shown to cause Wilms tumor, a rare kidney cancer that occurs in children. The findings identified mutations in the REST gene in 16 children with Wilms tumor.

Specific Genetic Alterations Observed in Papillary Renal-Cell Carcinomas

Specific Genetic Alterations Observed in Papillary Renal-Cell Carcinomas

Type 1 and type 2 carcinomas are characterized by specific genetic alterations; type 2 consists of at least three subtypes.

Forms of Meat Preparation May Increase Renal Cell Carcinoma Risk

Forms of Meat Preparation May Increase Renal Cell Carcinoma Risk

A recent study has linked an increased risk of kidney cancer to certain meat-cooking mutagens.

Model Developed for Predicting Toxicity-related Treatment Discontinuation in mRCC

Model Developed for Predicting Toxicity-related Treatment Discontinuation in mRCC

Independent risk factors for toxicity-related treatment discontinuation (TrTD) in patients with metastatic renal cell carcinoma (mRCC).

Questionnaire Effective in Assessing Adverse Events in Renal Cell Carcinoma

Questionnaire Effective in Assessing Adverse Events in Renal Cell Carcinoma

Frequent adverse events experienced by patients receiving tyrosine kinase inhibitors are hand-foot syndrome and mucositis/stomatitis.

Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 Years

Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 Years

Sunitinib and sorafenib may be associated with an increased risk of cardiovascular events in older patients with renal cell carcinoma (RCC).

New Drug Improves Outcome in Treatment Resistant Kidney Cancer

New Drug Improves Outcome in Treatment Resistant Kidney Cancer

A new drug is proven more effective than standard therapies for advanced kidney cancer in patients with demonstrated drug resistance.

Novel Immunotherapy Shows Promise Against Advanced Renal Cancer

Novel Immunotherapy Shows Promise Against Advanced Renal Cancer

In new clinical trial, Nivolumab raised median survival for patients with advanced renal-cell carcinoma.

Patient Disparity in Trials vs Clinic Raises Doubts on Kidney Cancer Drug Efficacy

Patient Disparity in Trials vs Clinic Raises Doubts on Kidney Cancer Drug Efficacy

Four drugs that were recently approved by the FDA for the treatment of kidney cancer are being doubted for their clinical application.

Sunitinib Plus Gemcitabine Active in Sarcomatoid, Poor-Risk Renal Cell Carcinoma

Sunitinib Plus Gemcitabine Active in Sarcomatoid, Poor-Risk Renal Cell Carcinoma

Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for aggressive renal cell carcinoma (RCC).

Robotic Inferior Vena Cava (IVC) Thrombectomy Successfully Removes Thrombus Associated With Kidney Cancer

Inferior vena cava (IVC) thrombectomy is typically is performed via a large open incision, but recently the procedure was successfully performed robotically, using only seven small incisions.

Cabozantinib Granted Breakthrough Therapy Designation for Kidney Cancer

Cabozantinib Granted Breakthrough Therapy Designation for Kidney Cancer

The FDA has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma (RCC).

Low Risk of Renal Dysfuntion in Patients With Wilms Tumor Undergoing Partial Nephrectomy

Low Risk of Renal Dysfuntion in Patients With Wilms Tumor Undergoing Partial Nephrectomy

Patients with unilateral Wilms tumor who underwent unilateral radical nephrectomy appear to have low risk for renal dysfunction.

Robotic IVC Thrombectomy Appears Successful in Patients With Kidney Cancer

Robotic IVC Thrombectomy Appears Successful in Patients With Kidney Cancer

Surgeons successfully performed an inferior vena cava (IVC) thrombectomy robotically in nine patients with kidney cancer.

Some Pediatric Patients With Wilms' Tumor Can Avoid Doxorubicin

Some Pediatric Patients With Wilms' Tumor Can Avoid Doxorubicin

Children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.

Study clarifies best treatments for uncommon kidney cancers

Study clarifies best treatments for uncommon kidney cancers

Head-to-head comparison offers clinicians much-needed clarity on the preferred first-line treatment of kidney cancers.

Stereotactic body radiation pioneered for deadly kidney cancer complication

Stereotactic body radiation pioneered for deadly kidney cancer complication

Two case studies have described what is believed to be the first reported successful use of stereotactic body radiation therapy for an oft-deadly kidney cancer complication.

Precision medication is effective for subset of adrenal cancer patients

A subset of adrenal cancer patients responded well to drug treatment in a phase 3 trial, giving some hope for addressing this aggressive form of cancer.

Urine test may detect kidney cancer early

Urine test may detect kidney cancer early

Researchers developed a noninvasive urine test that screens for kidney cancer.

Lycopene may decrease risk of renal cell carcinoma in postmenopausal women

Lycopene may decrease risk of renal cell carcinoma in postmenopausal women

A higher intake of lycopene in postmenopausal women may decrease the risk for developing renal cell carcinoma.

No benefit from adjuvant sunitinib, sorafenib in locally advanced renal cell carcinoma

No benefit from adjuvant sunitinib, sorafenib in locally advanced renal cell carcinoma

Use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma.

Close monitoring of renal tumors may provide alternative to surgery

Close monitoring of renal tumors may provide alternative to surgery

In situations where small renal tumors confined to the kidneys, active monitoring, as opposed to immediate surgery, is associated with low rates of tumor growth or mortality.

Active surveillance may be an alternative to surgery for localized renal tumors

Active surveillance may be an alternative to surgery for localized renal tumors

In patients likely to have surgery, close monitoring of small renal tumors is associated with low rates of cancer growth or mortality.

Genetic assay is predictive of prognosis for kidney cancer

Genetic assay is predictive of prognosis for kidney cancer

A test that has the potential to improve treatment of patients with clear cell renal cell carcinoma (ccRCC).

Organ preservation in kidney cancer more likely at facilities that are early adopters of robotic surgery

Patients with operable kidney cancers were more likely to have a partial nephrectomy, which is the recommended treatment for localized tumors, when treated in hospitals that were early adopters of robotic surgery, according to a new study.

Genetic sequence of rare kidney cancer reveals unique alterations involving telomerase

An international scientific collaboration has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer, providing new insights not only into this rare cancer but other types as well.

Less radical procedures control kidney cancer similarly to surgery

Needle-guided tumor destruction procedures offer near equivalent lengths of cancer control when compared with surgery for patients with small kidney cancer tumors.

Mutations in a gene essential for cell regulation cause kidney cancer in children

Mutations in a gene that helps regulate when genes are switched on and off in cells have been found to cause rare cases of Wilms tumor, the most common kidney cancer occurring in children.

Metabolic enzyme stops progression of most common kidney cancer

In an analysis of small molecules called metabolites, a research team identified an enzyme key to applying the brakes on tumor growth.

Robot-assisted surgery technique improves kidney cancer surgery

Robot-assisted surgery technique improves kidney cancer surgery

A novel robot-assisted surgery technique may help with removal to difficult to locate tumors.

Gene in brain linked to kidney cancer

Gene in brain linked to kidney cancer

A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer.

Brain development gene implicated in kidney cancer

Brain development gene implicated in kidney cancer

A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer.

Low cholesterol linked to worse survival in kidney cancer

People are often told to reduce their cholesterol to improve their health, but new research suggests that low cholesterol may increase kidney cancer patients' risk of dying from their disease.

Patients taking pazopanib for advanced renal cancer report better quality of life

Patients taking pazopanib for advanced renal cancer report better quality of life

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

Metastatic Cancer (Fact Sheet)

This fact sheet reviews common sites of cancer metastasis, methods of spread, treatment, and additional details.

Pazopanib tolerated best in kidney cancer study

A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.

Kidney cancer drugs demonstrate similar efficacy

Kidney cancer drugs demonstrate similar efficacy

Although pazopanib and sunitinib are similarly effective in patients with metastatic renal-cell cancer, pazopanib is associated with better safety and quality of life, according to a study.

Surgical options for kidney cancer clarified

Surgery is often the first step in treating kidney cancer, and new data questions whether removing only the tumor is better than removing the entire kidney.

Kidney-cancer surgery more precise with robotic ultrasound

Using robotic ultrasound probes for identification of kidney tumors during robotic partial nephrectomy offered the advantage of surgeon autonomy compared with the use of laparoscopic ultrasound probes.

Kidney-sparing surgery underused for patients who need it most

New study results show that partial kidney removal and energy-based techniques to destroy tumors are increasingly used to manage kidney disease. However, the patients most in need of kidney-sparing surgery are surprisingly still more likely to undergo total nephrectomy.

Trio of biomarkers may help to identify kidney cancer in early stages

A new immunoassay that tests for the presence of three biomarkers appears to be a valid screening method for the early detection of malignant kidney cancer. The immunoassay measured the levels of three potential biomarkers for kidney cancer.

Three biomarkers can detect kidney cancer with high accuracy

Three biomarkers can detect kidney cancer with high accuracy

Levels of three serum proteins are much higher in kidney cancer patients, lending a highly accurate diagnosis.

Sunitinib does not speed growth of renal cancer in humans

Animal studies have suggested that sunitinib may promote cancer growth and metastasis, but this does not appear to happen in humans.

"ICE" is key to new kidney-sparing cancer surgery

A surgical technique known as intracorporeal cooling and extraction (ICE) may reduce the need for conventional open surgery in kidney cancer.

Noninvasive test for kidney cancer may lessen need for surgery

A new radioactive tracer agent can be used with PET/CT to accurately detect clear cell renal cell carcinomas, the most common type of kidney cancer.

Three-way approach demystifies kidney cancer

Researchers looking at multiple different levels of changes in renal cell carcinoma are closer to determining how these tumors grow and survive.

Everolimus shrinks astrocytoma brain tumors

The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.

Black patients with kidney cancer have worse survival than whites

Among patients with renal cell carcinoma, whites consistently have a survival advantage over blacks, regardless of patient or tumor characteristics or surgical treatment. These findings suggest the need for additional efforts to prolong the survival of all patients with kidney cancer.

Active surveillance is viable alternative to surgery for small kidney masses

Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery. The overall and cancer specific survival rates are similar for both approaches.

"LESS" painful form of laparoscopy proven in kidney cancer

Laparoendoscopic single-site surgery (LESS) for removal of a cancerous kidney led to a less painful recovery than did traditional multiport laparoscopy.

Study links pancreas radiation to diabetes risk

Evidence points to a dose-response relation between radiation exposure of the pancreas and risk of diabetes in survivors of childhood cancers.

Enzyme may predict effectiveness of kidney cancer treatment

Levels of an enzyme already considered a risk factor for aggressive renal cell carcinoma may also indicate how well an mTOR inhibitor will work.

Drug combination not of benefit in inflammatory breast cancer

Adding pazopanib to lapatinib for inflammatory breast cancer produces greater toxicity than lapatinib alone with no significant clinical benefit.

FDA Update: May/June 2012

Drug Safety Communication on lenalidomide (Revlimid); FDA approval for pazopanib (Votrient)

Weight and inactivity impact cancer rates

Weight and inactivity impact cancer rates

Overall US cancer death rates have continued to decline since the early 1990s, but excess weight and lack of sufficient activity contribute to the increased incidence of many cancers.

Heart risks of cancer drugs underestimated

The system for monitoring adverse events in oncology clinical trials is in urgent need of reform, say the authors of a recent commentary.

More evidence shows aspirin might stave off cancer

Results from three new studies are consistent with earlier findings that aspirin can reduce cancer risk and, in some cases, metastasis.

Abscopal effect strengthens combination therapy in a melanoma patient

Combination therapy may be a promising treatment approach for patients with advanced melanoma who experience the abscopal effect.

Side effects of certain cancer drugs may be fatal

Sorafenib, sunitinib, and pazopanib have been found to carry a heightened risk of fatal complications, but the incidence remains low overall.

2002 to 2008 Saw Increase in Partial Nephrectomy Use

2002 to 2008 Saw Increase in Partial Nephrectomy Use

For patients with renal masses, use of partial nephrectomy increased from 15.3 to 24.7 percent.

Drug Approved for Advanced Kidney Cancer

Drug Approved for Advanced Kidney Cancer

Inlyta has been approved by the FDA to treat advanced renal cell carcinoma in patients who haven't responded to another drug.

Bevacizumab delays return of ovarian cancer

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.

ACS annual report says cancer mortality is decreasing

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.

Cancer risk doubles for organ-transplant recipients

Compared with the general population, recipients of a kidney, liver, heart, or lung transplant have twice as great a risk for diverse infection-related and unrelated cancers.

LATE-BREAKING NEWS: FDA revokes Avastin breast cancer indication

The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.

Bevacizumab label now warns of ovarian, osteonecrosis risks

The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.

FDA group stands against bevacuzimab for breast cancer

The Oncologic Drug Advisory Committee recommended that the FDA withdraw its approval of bevacizumab's indication for breast cancer.

Lymphocyte counts may be a prognostic marker for kidney cancer

Data from 516 people with the most common form of renal cell carcinoma demonstrated a strong relationship between low lymphocyte counts within 3 months prior to surgery and a poor prognosis.

New treatments for pancreatic cancer

New treatments for pancreatic cancer

FOLFIRINOX was more effective than gemcitabine in increasing survival and delaying disease progression in metastatic pancreatic cancer, plus new indications for everolimus and sunitinib.

Kidney cancer drug may provide much-needed treatment for mesothelioma

Temsirolimus, a kinase inhibitor commonly used to treat advanced renal cell carcinoma, may increase the effectiveness of chemotherapy administered in the treatment of mesothelioma.

Treatment algorithm helps manage tivozanib-related hypertension

Physicians and nursing staff effectively managed hypertension—an established target-related side effect of vascular endothelial growth factor receptor (VEGFR) inhibitors—using home blood pressure monitors and a treatment algorithm in patients enrolled in a phase 2 randomized discontinuation trial of tivozanib, a potent and selective inhibitor of all three VEGFR kinases. The data were presented at the Oncology Nursing Society 36th Annual Congress.

Overall cancer mortality rates decrease, but incidence of some cancers increases

Overall, cancer incidence rates fell approximately 1% annually and overall death rates decreased by an average of 1.6% annually between 2003 and 2007.

Nephron-sparing surgery preserves kidney function in large tumors, too

Nephron-sparing surgery now appears to benefit long-term kidney function in cases involving renal tumors larger than 4 cm—even in elderly patients.

Carefully consider and monitor bevacizumab use

Using bevacizumab in combination with chemotherapy or biological therapy raises the risk of treatment-related death—but the agent's potential benefits may outweigh the relatively low absolute risk.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs